Traffic Lights - Latest Updates

Last updated: 26/04/2018

Other updates on this site
Drug Name Classification Clinical Indication Comments
AFLIBERCEPT (Eylea®) (UPDATED) Red Wet age related macular degeneration. Diabetic macular oedema. Macular oedema due to central retinal vein occlusion and branch retinal vein occlusion. Choroidal neovascularisation.

In line with NICE TA294, NICE TA346, NICE TA305, NICE TA409, NICE TA486

ALIMEMAZINE (UPDATED) Green Conditional Various

Historic patients who have tried or not been suitable for other sedating antihistamines or melatonin. GP to continue prescribing.
Important: Patients currently taking alimemazine should be discussed with the specialist and not have treatment stopped abruptly without a review.

ALIMEMAZINE (UPDATED) Red Various

Historic patients who have not tried or been considered for alternatives. Patients to be reviewed by secondary care. Secondary care to prescribe if continuing treatment required.
Important: Patients currently taking alimemazine should be discussed with the specialist and not have treatment stopped abruptly without a review.

ALIMEMAZINE (UPDATED) Black Various

Current patients should be discussed with the prescribing specialist and not have treatment stopped abruptly without appropriate review.

ALPROSTADIL uretheral sticks and injections (NEW) Green Erectile dysfunction

Not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff. The prescription must be endorsed ‘SLS’.

Maximum 4 doses per month to be prescribed.

BASILIXIMAB (Simulect®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

BELATACEPT (Nulojix®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

BIOSIMILAR TRASTUZUMAB (Ontruzant®) (NEW) Black for HER2 positive metastatic and early stage breast cancer, HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
BUDESONIDE 64mcg NASAL SPRAY (Benacort®) (NEW) Black
BUDESONIDE and FORMETEROL (Fobumix®) Easyhaler (NEW) Green Asthma
CARIPRAZINE (NEW) Black Schizophrenia
CIPROFLOXACIN 2mg/ml ear drops (Cetraxal ®) (NEW) Black Acute otitis media

Not yet reviewed

CLADRIBINE (NEW) Red Relapsing-remitting multiple sclerosis

In line with NICE TA 493

DUPILUMAB (Dupixent®) (NEW) Black
EMICIZUMAB (Hemlibra®) (NEW) Black For prophylaxis of bleeding episodes
ENOXAPARIN BECAT prefilled syringes (NEW) Black Parenteral anticoagulant
EVEROLIMUS (Certican®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

FIBRINOGEN (Riastap®) (NEW) Red Treatment of severe bleeding in acquired hypofibrinogenemia resulting from operative interventions, in particular after cardiac surgery
FLUTICASONE / AZELASTINE NASAL SPRAY (Dymista®) (UPDATED) Green Rhinitis

To be used in line with the Allergic Rhinitis Pathway

GLECAPREVIR-PIBRENTASVIR (Maviret®) (NEW) Red Hepatitis C

In line with NICE TA 499

GOLIMUMAB (NEW) Red Non-radiographic axial spondyloarthritis

In line with NICE TA 497

GUSELKUMAB (Tremfya®) (NEW) Black Moderate to severe plaque psoriasis in adults
HISTIDINE TRYTOPHAN KETOGLUTARATE MANITOL (Custodiol®) (NEW) Red For myocardial protection in complex cardiac surgery. For organ preservation in transplant surgery
HYDROCORTISONE (Alkindi®)(Granules in capsules for opening) (NEW) Black Adrenal insufficiency in infants
INTERFERON GAMMA (Immukin®) (NEW) Red For mycobacterial infections and pulmonary and miliary
LEVETIRACETAM (NEW) Green Conditional Palliative care in line with guidance

Conditional on recommendation from palliative care team.
Palliative Care Prescribing

MYCOPHENOLATE (UPDATED) Amber Full SCA Immunosuppression following renal transplantation

Exception agreed to red status: Full shared care to allow GPs to continue supplying to historical patients still on shared care where appropriate for patient and the GP agrees.

Full SCA

MYCOPHENOLATE (NEW) Red Immunosuppression following renal transplantation
NALOXONE (NEW) Green Conditional Palliative care in line with guidance.

Conditional on recommendation from palliative care team.
Palliative Care Prescribing

NALTREXONE / BUPROPION M/R (Mysimba®) (NEW) Black Managing obesity

NICE TA 494 not supported for managing obesity in adults

OCRELIZUMAB (Ocrevus®) (NEW) Black
PATIROMER (Veltassa®) (NEW) Black
PIRFENIDONE (Esbriet®) (UPDATED) Red For Idiopathic pulmonary fibrosis

In line with NICE TA 504 (Replaces NICE TA 282)

QUETIAPINE (NEW) Green Conditional Palliative care in line with guidance.

Conditional on recommendation from palliative care team.
Palliative Care Prescribing

RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN (Thymoglobuline®) (NEW) Red Immunosuppressive therapy for Kidney Transplant in Adults and Children/Young People

In line with NICE TA 481, NICE TA 482

SOFOSBUVIR–VELPATASVIR-VOXILAPREVIR (Vosevi®) (NEW) Red For Chronic hepatitis C

IMPLEMENTATION from 21st May 2018
In line with NICE TA 504

TIVOZANIB (Fotivda®) (NEW) Black Advanced renal cell carcinoma

Not yet reviewed

ULIPRISTAL ACETATE (Esmya®) (UPDATED) Amber Simple Pre-operative treatment of uterine fibroids.
Review appropriateness of treatment after 3/12

Existing patients only

ULIPRISTAL ACETATE (Esmya®) (UPDATED) Black Uterine fibroids.

New patients only.
MHRA healthcare professional letter

 

Other Updates on this Website

Recent documents from LMSG and TAS

Topiramate and Valproate Flow Chart (102 KB)

Ensuring female patients on preparations containing Valproate or Topiramate receive necessary counselling. Version 1 uploaded April 2018. Please be aware this document is now under review following the MHRA press release on 24th April; https://www.gov.uk/government/news/valproate-banned-without-the-pregnancy-prevention-programme

Date added: 17th Apr 2018

About the Leicestershire Medicines Strategy Group

In common with other local health communities, the Leicestershire Medicines Strategy Group (LMSG) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.

Leicestershire Health Community comprises the three Clinical Commissioning Groups, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LMSG has been in place since 2005. Learn more